Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 4Urinary Bladder Neoplasms 3Recurrence 2Lung Neoplasms 2Urothelial Cancer 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Prednisone 112Docetaxel 87Leuprolide 79enzalutamide 72Abiraterone Acetate 67bicalutamide 53Goserelin 50acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 42Radiotherapy 39abiraterone 28Magnetic Resonance Spectroscopy 27Gonadotropin-Releasing Hormone 24gallium 68 PSMA-11 23apalutamide 22Androgen Antagonists 22luprolide acetate gel depot 21sipuleucel-T 20Radiosurgery 20Triptorelin Pamoate 18cabazitaxel 17cabozantinib 16Radiotherapy, Intensity-Modulated 16Flutamide 16pembrolizumab 15radium Ra 223 dichloride 14Prednisolone 14Nivolumab 14Dutasteride 14Dexamethasone 14Radiation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Prostatic Neoplasms × vinflunine × Clear all
NCT00545766 2021-12-16

Vinflunine in Hormone Refractory Prostate Cancer (HRPC)

SCRI Development Innovations, LLC

Phase 2 Completed
41 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡